PMID- 17293736
OWN - NLM
STAT- MEDLINE
DCOM- 20070403
LR  - 20191110
IS  - 1550-5049 (Electronic)
IS  - 0889-4655 (Linking)
VI  - 21
IP  - 6
DP  - 2006 Nov-Dec
TI  - Key clinical insights from the sudden cardiac death in heart failure trial.
PG  - 463-8
AB  - Heart failure (HF) is a common and lethal syndrome. Those with moderate left 
      ventricular dysfunction have a substantial risk of premature and sudden death, 
      approximately 25% over 2.5 years. Fifty percent of these deaths are thought to be 
      sudden due to dysrhythmias, which may be preventable. As a consequence, patients 
      with HF represent the largest, single identifiable population of patients that 
      can be targeted for primary prevention of sudden cardiac death. A trial known as 
      SCD-HeFT (The Sudden Cardiac Death in Heart Failure Trial), sponsored by the 
      National Heart Lung and Blood Institute of the National Institutes of Health, was 
      designed to evaluate the value of the prophylactic amiodarone or implantable 
      cardioverter defibrillator therapy in patients with HF. This article reviews 4 
      key clinical insights highlighted by the SCD-HeFT results: (1) ramifications of 
      implantable cardioverter defibrillator use in patients with New York Heart 
      Association (NYHA) class II HF; (2) the value or lack thereof of implantable 
      cardioverter defibrillator therapy in patients with NYHA class III HF; (3) the 
      danger of amiodarone drug therapy in patients with NYHA class III HF; and (4) the 
      significant value of basic medical management, when well implemented, in 
      prolonging life in this population. In addition, future directions in the 
      evaluation and management of patients with moderate to severe HF are addressed.
FAU - Anderson, Jill
AU  - Anderson J
AD  - Clinical Affairs, Seattle Institute for Cardiac Research, Seattle, WA 98103-4819, 
      USA. jander@sicr.org
FAU - Bardy, Gust H
AU  - Bardy GH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Cardiovasc Nurs
JT  - The Journal of cardiovascular nursing
JID - 8703516
RN  - 0 (Anti-Arrhythmia Agents)
RN  - N3RQ532IUT (Amiodarone)
SB  - IM
MH  - Aged
MH  - Amiodarone/adverse effects/*therapeutic use
MH  - Anti-Arrhythmia Agents/adverse effects/*therapeutic use
MH  - Death, Sudden, Cardiac/*etiology/*prevention & control
MH  - *Defibrillators, Implantable
MH  - Female
MH  - Heart Failure/*complications
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
RF  - 6
EDAT- 2007/02/13 09:00
MHDA- 2007/04/04 09:00
CRDT- 2007/02/13 09:00
PHST- 2007/02/13 09:00 [pubmed]
PHST- 2007/04/04 09:00 [medline]
PHST- 2007/02/13 09:00 [entrez]
AID - 00005082-200611000-00009 [pii]
AID - 10.1097/00005082-200611000-00009 [doi]
PST - ppublish
SO  - J Cardiovasc Nurs. 2006 Nov-Dec;21(6):463-8. doi: 
      10.1097/00005082-200611000-00009.